Bayer AG vs. Teva: Cardiovascular Patent Dispute Ends in Dismissal

Case Overview

A high-stakes pharmaceutical patent infringement dispute between two global industry giants concluded quietly but consequentially on January 8, 2026. In Bayer AG v. Teva Pharmaceutical Industries, Ltd. (Case No. 1:23-cv-00551), Bayer and its co-plaintiffs—including Janssen Pharmaceuticals—voluntarily dismissed their infringement action against Teva with prejudice before the Delaware District Court, while Teva’s counterclaims were dismissed without prejudice.

The case centered on U.S. Patent No. US10828310B2, covering a method for reducing the risk of cardiovascular events—a therapeutically and commercially critical area of pharmaceutical innovation. After nearly 965 days of litigation, both parties agreed to bear their own costs and attorneys’ fees, leaving no disclosed damages award or injunctive relief on record.

For patent attorneys, in-house IP counsel, and pharmaceutical R&D leaders, this outcome reflects broader strategic realities in ANDA-adjacent pharmaceutical patent litigation: settlement-by-dismissal frequently signals confidential licensing arrangements or commercial recalibrations rather than a clear win or loss on the merits.

The Parties

The Patent at Issue

This case involved U.S. Patent No. US10828310B2 (Application No. US16/264032), covering methods for reducing the risk of cardiovascular events in patients. This patent’s claims cover therapeutic methods with clinical specificity—a category that can be particularly complex to construe and enforce, especially when a generic manufacturer’s product labeling is the primary evidence of induced infringement.

The Verdict & Legal Analysis

Outcome

The case was terminated via stipulated dismissal under Federal Rules of Civil Procedure 41(a)(1) and 41(c). Bayer’s claims against Teva were dismissed with prejudice, meaning they cannot be re-filed. Teva’s counterclaims, likely including invalidity and unenforceability defenses, were dismissed without prejudice, preserving Teva’s ability to reassert them if necessary. No damages were disclosed, and each party agreed to bear its own costs and attorneys’ fees.

Legal Significance

The asymmetric dismissal structure—plaintiff’s claims with prejudice, defendant’s counterclaims without prejudice—is a recognizable fingerprint of negotiated pharmaceutical patent resolutions. It often accompanies confidential licensing or market entry agreements, where the generic manufacturer receives an authorized entry date in exchange for withdrawing its challenge.

For practitioners, this outcome highlights the prevalence of pre-trial resolution in Hatch-Waxman litigation even after extended discovery periods. The case reinforces that method-of-treatment patents, while powerful prosecution tools, can present enforcement challenges when infringement depends on labeling-driven induced infringement theories that are difficult to establish without trial. No judicial finding on validity, claim construction, or infringement was issued, meaning this case sets no direct precedent on the merits of US10828310B2.